Pharming Group (NASDAQ:PHAR) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research note released on Thursday,Benzinga reports. They currently have a $37.00 price target on the stock.

Several other research firms also recently commented on PHAR. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. Oppenheimer lifted their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th.

Pharming Group Trading Up 0.1 %

Shares of Pharming Group stock opened at $8.81 on Thursday. The firm’s 50 day moving average is $8.91 and its 200 day moving average is $8.61. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.30. The firm has a market capitalization of $599.29 million, a PE ratio of -33.88 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Equities research analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.